Moxazocine

Moxazocine
Identifiers
  • (1S,9R,13S)-10-(cyclopropylmethyl)-13-methoxy-1-methyl-10-azatricyclo[7.3.1.02,7]trideca-2,4,6-trien-4-ol
CAS Number
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H25NO2
Molar mass287.403 g·mol−1
3D model (JSmol)
  • Oc1ccc2C[C@H]3N(CC[C@@](C)(c2c1)[C@@H]3OC)CC4CC4
  • InChI=1S/C18H25NO2/c1-18-7-8-19(11-12-3-4-12)16(17(18)21-2)9-13-5-6-14(20)10-15(13)18/h5-6,10,12,16-17,20H,3-4,7-9,11H2,1-2H3/t16-,17-,18+/m1/s1
  • Key:IOZWXJXXVLARQC-KURKYZTESA-N

Moxazocine (BL-4566) is an opioid analgesic of the benzomorphan family which was never marketed.[1] It acts as a partial agonist or mixed agonist/antagonist of the opioid receptors and binds preferentially to the κ-opioid receptor.[2] Despite its failure to reach the market, clinical studies demonstrated moxazocine to be approximately 10x as potent by weight as morphine as an analgesic.[3]

  1. ^ Dictionary of Pharmacological Agents Volume 2. CRC Press. 1996-11-21. p. 1382. ISBN 978-0-412-46630-4. Retrieved 22 April 2012.
  2. ^ Hayes AG, Sheehan MJ, Tyers MB (August 1987). "Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonists". British Journal of Pharmacology. 91 (4): 823–832. doi:10.1111/j.1476-5381.1987.tb11281.x. PMC 1853585. PMID 2822190.
  3. ^ Dobkin AB, Esposito BF, Noveck RJ, Caruso FS (October 1977). "Moxazocine and morphine in patients with severe postoperative pain". Current Therapeutic Research. 22 (4): 469–478.